CN111956664A - Composition for pets and application thereof - Google Patents
Composition for pets and application thereof Download PDFInfo
- Publication number
- CN111956664A CN111956664A CN201911222101.2A CN201911222101A CN111956664A CN 111956664 A CN111956664 A CN 111956664A CN 201911222101 A CN201911222101 A CN 201911222101A CN 111956664 A CN111956664 A CN 111956664A
- Authority
- CN
- China
- Prior art keywords
- solution
- pet
- cannabidiol
- parts
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 239000007921 spray Substances 0.000 claims abstract description 57
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims abstract description 52
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims abstract description 52
- 229950011318 cannabidiol Drugs 0.000 claims abstract description 52
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims abstract description 52
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims abstract description 52
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 claims abstract description 44
- HHVIBTZHLRERCL-UHFFFAOYSA-N sulfonyldimethane Chemical compound CS(C)(=O)=O HHVIBTZHLRERCL-UHFFFAOYSA-N 0.000 claims abstract description 42
- 239000002994 raw material Substances 0.000 claims abstract description 26
- 239000005844 Thymol Substances 0.000 claims abstract description 22
- 229960000790 thymol Drugs 0.000 claims abstract description 22
- MTDHILKWIRSIHB-UHFFFAOYSA-N (5-azaniumyl-3,4,6-trihydroxyoxan-2-yl)methyl sulfate Chemical compound NC1C(O)OC(COS(O)(=O)=O)C(O)C1O MTDHILKWIRSIHB-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960002849 glucosamine sulfate Drugs 0.000 claims abstract description 20
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229940041616 menthol Drugs 0.000 claims abstract description 17
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims abstract description 14
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims abstract description 14
- 229930003471 Vitamin B2 Natural products 0.000 claims abstract description 14
- 229960002477 riboflavin Drugs 0.000 claims abstract description 14
- 239000011716 vitamin B2 Substances 0.000 claims abstract description 14
- 235000019164 vitamin B2 Nutrition 0.000 claims abstract description 14
- 208000025157 Oral disease Diseases 0.000 claims abstract description 13
- 208000030194 mouth disease Diseases 0.000 claims abstract description 13
- 229910052709 silver Inorganic materials 0.000 claims abstract description 13
- 239000004332 silver Substances 0.000 claims abstract description 13
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 9
- 230000036506 anxiety Effects 0.000 claims abstract description 9
- 206010003246 arthritis Diseases 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims description 44
- 238000003756 stirring Methods 0.000 claims description 41
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 28
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 238000001914 filtration Methods 0.000 claims description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 13
- 239000006184 cosolvent Substances 0.000 claims description 13
- 239000000796 flavoring agent Substances 0.000 claims description 12
- 235000013355 food flavoring agent Nutrition 0.000 claims description 11
- 239000004376 Sucralose Substances 0.000 claims description 10
- 235000019408 sucralose Nutrition 0.000 claims description 10
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 9
- 229960004873 levomenthol Drugs 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 7
- 229930003270 Vitamin B Natural products 0.000 claims description 7
- 235000019156 vitamin B Nutrition 0.000 claims description 7
- 239000011720 vitamin B Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 6
- 108010011485 Aspartame Proteins 0.000 claims description 5
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 claims description 5
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 5
- 239000000605 aspartame Substances 0.000 claims description 5
- 235000010357 aspartame Nutrition 0.000 claims description 5
- 229960003438 aspartame Drugs 0.000 claims description 5
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 5
- 229960001462 sodium cyclamate Drugs 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 238000001228 spectrum Methods 0.000 claims description 3
- 241000218236 Cannabis Species 0.000 claims 3
- CVCQAQVBOPNTFI-AAONGDSNSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;sulfuric acid Chemical compound OS(O)(=O)=O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O CVCQAQVBOPNTFI-AAONGDSNSA-N 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 235000019634 flavors Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 230000036541 health Effects 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 5
- -1 silver ions Chemical class 0.000 abstract description 4
- 206010022998 Irritability Diseases 0.000 abstract description 3
- 230000036651 mood Effects 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 230000001914 calming effect Effects 0.000 abstract description 2
- 210000002200 mouth mucosa Anatomy 0.000 abstract description 2
- 230000002040 relaxant effect Effects 0.000 abstract description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 82
- 230000000052 comparative effect Effects 0.000 description 26
- 238000002360 preparation method Methods 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 210000000214 mouth Anatomy 0.000 description 9
- 239000008213 purified water Substances 0.000 description 9
- 229960004756 ethanol Drugs 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 6
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 6
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 210000004379 membrane Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 201000001245 periodontitis Diseases 0.000 description 5
- 206010006326 Breath odour Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000032139 Halitosis Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 229960005150 glycerol Drugs 0.000 description 4
- 240000004308 marijuana Species 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 208000002925 dental caries Diseases 0.000 description 3
- 238000004332 deodorization Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000002064 Dental Plaque Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000605986 Fusobacterium nucleatum Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000007117 Oral Ulcer Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 150000004263 amino monosaccharides Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003260 anti-sepsis Effects 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 229930003827 cannabinoid Natural products 0.000 description 2
- 239000003557 cannabinoid Substances 0.000 description 2
- 229940065144 cannabinoids Drugs 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001612 chondrocyte Anatomy 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000001877 deodorizing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000001503 joint Anatomy 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Natural products CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000009044 synergistic interaction Effects 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 1
- 241001529821 Agastache Species 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- REOZWEGFPHTFEI-JKSUJKDBSA-N Cannabidivarin Chemical compound OC1=CC(CCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-JKSUJKDBSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 206010011409 Cross infection Diseases 0.000 description 1
- ZROLHBHDLIHEMS-UHFFFAOYSA-N Delta9 tetrahydrocannabivarin Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCC)=CC(O)=C3C21 ZROLHBHDLIHEMS-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 235000010254 Jasminum officinale Nutrition 0.000 description 1
- 240000005385 Jasminum sambac Species 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 244000242564 Osmanthus fragrans Species 0.000 description 1
- 235000019083 Osmanthus fragrans Nutrition 0.000 description 1
- 240000000968 Parkia biglobosa Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241001162994 Rugosus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241001146210 Senecio scandens Species 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000014151 Stomatognathic disease Diseases 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000005456 alcohol based solvent Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 201000003465 angular cheilitis Diseases 0.000 description 1
- 210000001264 anterior cruciate ligament Anatomy 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 238000001266 bandaging Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 1
- 229940116229 borneol Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- REOZWEGFPHTFEI-UHFFFAOYSA-N cannabidivarine Natural products OC1=CC(CCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 REOZWEGFPHTFEI-UHFFFAOYSA-N 0.000 description 1
- QXACEHWTBCFNSA-SFQUDFHCSA-N cannabigerol Chemical compound CCCCCC1=CC(O)=C(C\C=C(/C)CCC=C(C)C)C(O)=C1 QXACEHWTBCFNSA-SFQUDFHCSA-N 0.000 description 1
- YJYIDZLGVYOPGU-UHFFFAOYSA-N cannabigeroldivarin Natural products CCCC1=CC(O)=C(CC=C(C)CCC=C(C)C)C(O)=C1 YJYIDZLGVYOPGU-UHFFFAOYSA-N 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229960004242 dronabinol Drugs 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 239000010794 food waste Substances 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003400 hallucinatory effect Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000001726 jatropha manihot extract Substances 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000002159 nanocrystal Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 108010034764 nitric acid reductase Proteins 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940111617 oregano oil Drugs 0.000 description 1
- 239000010661 oregano oil Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940027779 persimmon extract Drugs 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 210000002967 posterior cruciate ligament Anatomy 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 229940106668 yucca extract Drugs 0.000 description 1
- 229940100530 zinc ricinoleate Drugs 0.000 description 1
- GAWWVVGZMLGEIW-GNNYBVKZSA-L zinc ricinoleate Chemical compound [Zn+2].CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O.CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O GAWWVVGZMLGEIW-GNNYBVKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/38—Silver; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
Abstract
The invention relates to a composition for pets and application thereof. The composition for pet comprises cannabidiol-containing raw material, dimethyl sulfone, glucosamine sulfate, menthol, thymol, vitamin B2 and active silver ions. The composition for the pet has the advantages that various components are matched with each other and synergized, so that oral diseases of the pet can be prevented and treated, oral health of the pet can be protected, various symptoms caused by arthritis of the pet can be effectively improved, and meanwhile, the composition has the effects of relieving the irritability and anxiety of the pet and calming and relaxing mood of the pet. The composition can be used for preparing pet spray, can be administered through oral mucosa, and has quick action and high bioavailability.
Description
Technical Field
The invention belongs to the technical field of veterinary drugs, and particularly relates to a composition for pets and application thereof.
Background
Oral diseases are the most common diseases in pet health examination, and more than 85% of pets over 3 years old have symptoms of oral diseases, while all dogs and cats are easy to suffer from oral diseases, and the number of small dogs is the largest. Veterinary dental professionals believe that the teeth of small dogs are too large for their entire oral cavity, thus necessitating tighter interproximal alignment and a consequent increase in the incidence of oral disease. Common dental diseases include: periodontal disease, gingivitis, tooth decay, mouth ulcers, angular stomatitis, etc., most of which are caused by oral bacteria. Bacteria breed in the oral cavity due to food residues to form volatile sulfides, so that halitosis is caused; bacteria are adsorbed on teeth and gum for a long time to generate dental plaque; dental plaque accumulates and mineralizes to form hard calculus; bacterial reproduction further triggers inflammation and infection, worsening oral health; bacteria also enter the blood stream through blood vessels near the teeth and gums and circulate to vital organs, affecting health. The close contact between human and pet is very easy to cause the cross infection of bacteria. Scientists at cornell university in the united states warn that most dogs in fact have periodontitis. They pointed out that if the owner kisses the dog or the dog licks the face of the owner, it is possible that some dangerous oral bacteria may be transmitted to the body and cause the owner to suffer from oral diseases.
Osteoarthritis is a degenerative osteoarticular disease in pet dogs and a more common and frequent disease in dogs. In fact, osteoarthritis can occur in pets of different breeds due to improper feeding, athletic injuries, and age-related increases in the pets, causing stiffness in the pet's limbs, swelling of the joints, pain when touched, excessive licking of a part, inflexibility of the limbs, slight tremor, loss of appetite, and irritability.
Anxiety is not specific to humans and pets occasionally experience anxiety, particularly pets who have been abused and neglected, more easily because of minor anxiety, and thus emotional violence, which may bark and disturb the population, or even at home.
CN105311245A discloses a safe and healthy spray containing traditional Chinese medicine components, which fundamentally solves the problem of halitosis of dogs from oral cavity and digestion. Is prepared from 5-25 parts of mint leaves, 5-15 parts of jasmine flowers, 5-18 parts of sweet osmanthus, 5-25 parts of agastache rugosus, 5-10 parts of borneol, 5-10 parts of white radish, 5-10 parts of clove, 5-10 parts of green tea, 20-90 parts of tea water, 1-10 parts of dried orange peel and 1-5 parts of yeast.
CN109646361A discloses a composite biological deodorization spray for pets, which is suitable for solving the problems of dog and cat halitosis, body odor, feces odor and the like, and a preparation method thereof, wherein the deodorization spray comprises, by mass, 5-8% of yucca extract, 4-5% of green tea extract, 6-8% of oregano oil extract, 4-5% of persimmon extract, 4-5% of horseradish extract, 3-4% of zinc ricinoleate, 5-6% of emulsifier, 1-2% of stabilizer, 1-2% of pH value regulator, and the balance of purified water. The deodorizing spray has good deodorizing performance, can effectively inhibit and kill pathogenic microorganisms, and can radically inhibit the generation of odor.
Most of the pet spray products sold in the market at present are single products for preventing and treating diseases of one aspect of the oral cavity, such as deodorization, caries prevention and the like, and are lack of comprehensive products for protecting the health of pets.
Disclosure of Invention
In view of the shortcomings of the prior art, the invention aims to provide a composition for pets and application thereof. The pet composition can prevent and treat oral diseases of pets, protect the oral health of the pets, effectively improve the joint stiffness symptoms of the pets, relieve the anxiety of the pets, calm and relieve the mood of the pets, and has a good effect on protecting the health of the pets.
In order to achieve the purpose, the invention adopts the following technical scheme:
in one aspect, the present invention provides a composition for pets comprising a cannabidiol-containing material, dimethyl sulfone, glucosamine sulfate, menthol, thymol, vitamin B2, and active silver.
The raw material containing cannabidiol can be selected from cannabidiol pure product, water-soluble cannabidiol, industrial cannabis flower and leaf extract or cannabidiol-containing product such as full spectrum cannabis oil. The full spectrum type cannabis oil is industrial cannabis oil which mainly contains cannabinoids such as cannabidiol, cannabidivarin, cannabigerol and tetrahydrocannabidivarin, and contains active ingredients such as flavone and terpenoids. The water-soluble cannabidiol is prepared by adopting solubilizing technologies such as a surfactant, a nano crystal, a clathrate compound, a micro emulsion, a solid dispersion and the like.
The active silver comprises active silver ions and active colloidal silver.
Preferably, the composition for pets comprises, by mass, 0.1-0.3 part of raw material containing cannabidiol, 3-8 parts of dimethyl sulfone, 3-8 parts of glucosamine sulfate, 0.02-0.15 part of menthol, 0.02-0.1 part of thymol, 0. 20.001-0.015 part of vitamin B and 0.1 x 10 parts of active silver-7-50×10-7And (4) portions are obtained.
The raw material containing cannabidiol can be 0.1 part, 0.15 part, 0.2 part, 0.25 part or 0.3 part by weight. Any other point value within the range can be selected, and the description is not repeated herein.
The raw material containing cannabidiol is calculated by compound cannabidiol in parts by mass.
The mass portion of the dimethyl sulfone can be 3 parts, 4 parts, 5 parts, 6 parts, 7 parts or 8 parts. Any other point value within the range can be selected, and the description is not repeated herein.
The glucosamine sulfate can be prepared in 3 parts, 4 parts, 5 parts, 6 parts, 7 parts or 8 parts by weight. Any other point value within the range can be selected, and the description is not repeated herein.
The menthol may be present in an amount of 0.02 parts, 0.04 parts, 0.05 parts, 0.06 parts, 0.08 parts, 0.10 parts, 0.12 parts, 0.13 parts, 0.15 parts, or the like, by mass. Any other point value within the range can be selected, and the description is not repeated herein.
The thymol can be 0.02 part, 0.04 part, 0.05 part, 0.06 part, 0.08 part or 0.10 part by mass. Any other point value within the range can be selected, and the description is not repeated herein.
The vitamin B2 may be present in an amount of 0.001 parts, 0.002 parts, 0.003 parts, 0.005 parts, 0.008 parts, 0.010 parts, 0.012 parts, 0.013 parts, 0.014 parts, 0.015 parts, or the like, by mass. Any other point value within the range can be selected, and the description is not repeated herein.
The active silver can be 0.1 multiplied by 10 in mass portion-7Portion, 0.2X 10-7Portion, 0.3X 10-71 × 10 portions of-7Portion, 10X 10-7Portion, 20X 10-7Portion or 50X 10-7And (4) parts and the like. Any other point value within the range can be selected, and the description is not repeated herein. The active silver is active silver ions or colloidal silver.
Cannabidiol (CBD) is one of cannabinoids, and has a molecular formula of C21H30O2The compound is a pale yellow resin or crystal, is usually extracted from natural plant hemp, can be artificially synthesized, has various pharmacological activities, is almost insoluble in water, and is dissolved in organic solvents such as ethanol, methanol, ether, benzene, chloroform, petroleum ether and the like. The structural formula is shown as the following formula I:
cannabidiol is completely different from tetrahydrocannabinol, has no hallucinogenic effect, and has good pharmacological activity in the aspects of spasm, anxiety/depression, inflammation, cancer, virus resistance, pain relief, rheumatoid arthritis, multiple sclerosis, epilepsy, particularly intractable epilepsy and the like.
The menthol has the functions of refreshing breath, cooling and relieving itching, and has certain sterilization and antisepsis functions. Thymol, also known as thymol, originally isolated from the plant senecio scandens, is a monoterpene which is a phenol derivative of p-cymene (p-cymene). The substance has antifungal and antibacterial effects. Pets lacking vitamin B are easy to have oral cavity related problems, such as oral ulcer, halitosis and the like, and timely supplement can prevent the oral diseases.
Dimethyl sulfone (MSM), an organic sulfide, is widely present in various organs and tissues of the human body, such as bones, muscles, skin, etc., is a raw material for synthesizing amino acids of the human body, and is also a substance essential for synthesizing collagen of the human body. It has been shown that dimethyl sulfone, as a supplement, is particularly effective in relieving joint pain and eliminating joint inflammation. Glucosamine sulfate is a natural amino monosaccharide and is an important component necessary for synthesizing proteoglycan in the articular cartilage matrix. The amino monosaccharide can stimulate chondrocyte to produce glycoprotein with normal polymer structure, inhibit certain enzymes (such as collagenase and phospholipase A2) capable of damaging articular cartilage, inhibit superoxide free radical production of damaged cells, prevent damage of chondrocyte caused by corticoids and certain non-steroidal anti-inflammatory drugs, and reduce release of endotoxin factor of damaged cells.
The active silver is a high-efficiency bactericide, can be combined with cell walls/membranes of pathogenic bacteria, can directly enter thalli, and can be rapidly combined with sulfydryl of oxygen metabolism enzyme to inactivate the enzyme and block respiratory metabolism to cause the enzyme to suffocate.
According to the invention, the cannabidiol raw material is creatively matched with the active substances of menthol, thymol, vitamin B, dimethyl sulfone, glucosamine sulfate and colloidal silver, so that the synergistic interaction effect among the raw materials can be exerted, the comprehensive effect of the product on preventing and treating oral diseases, improving arthritis and relieving anxiety of pets is maximized, and the product is multifunctional and all-around product for protecting the health of pets. Specifically, the menthol, the thymol, the vitamin B and the colloidal silver in the product components have certain sterilization and antisepsis effects or can prevent and treat oral diseases, but the effects can be obviously realized when the menthol, the thymol, the vitamin B and the colloidal silver are mutually matched, especially when the menthol, the thymol, the vitamin B and the colloidal silver are compatible with cannabidiol; both the dimethyl sulfone and the glucosamine sulfate in the product have the effect of relieving joint pain or eliminating joint inflammation, but the effect can be obviously realized when the dimethyl sulfone and the glucosamine sulfate are compatible, particularly when the dimethyl sulfone and the glucosamine sulfate are compatible with cannabidiol.
In another aspect, the present invention provides a pet spray comprising a composition for pets as described above, a co-solvent, and water.
Preferably, the pet spray comprises the following components in mass concentration:
the balance of cosolvent and water;
wherein the cosolvent accounts for 1-7% of the volume ratio of the pet spray.
The raw material containing cannabidiol is calculated by compound cannabidiol in parts by mass.
When the components of the spray are combined according to the mass ratio, the synergistic effect can be more remarkable.
The mass concentration of the raw material containing cannabidiol may be 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, or the like. Any other point value within the range can be selected, and the description is not repeated herein. The raw material containing cannabidiol is preferably water-soluble cannabidiol.
The mass concentration of the dimethyl sulfone may be 3%, 4%, 5%, 6%, 7%, 8%, or the like. Any other point value within the range can be selected, and the description is not repeated herein.
The glucosamine sulfate can be present at a mass concentration of 3%, 4%, 5%, 6%, 7%, 8%, or the like. Any other point value within the range can be selected, and the description is not repeated herein.
The mass concentration of menthol may be 0.02%, 0.04%, 0.05%, 0.06%, 0.08%, 0.10%, 0.12%, 0.13%, 0.15%, or the like. Any other point value within the range can be selected, and the description is not repeated herein.
The mass concentration of thymol can be 0.02%, 0.04%, 0.05%, 0.06%, 0.08%, 0.10%, etc. Any other point value within the range can be selected, and the description is not repeated herein.
The vitamin B2 may have a mass concentration of 0.001%, 0.002%, 0.003%, 0.005%, 0.008%, 0.010%, 0.012%, 0.013%, 0.014%, 0.015% or the like. Any other point value within the range can be selected, and the description is not repeated herein.
The mass concentration of the active silver may be 0.1ppb, 0.2ppb, 0.5ppb, 1ppb, 10ppb, 20ppb, 30ppb, 40ppb, or 50ppb, or the like. Any other point value within the range can be selected, and the description is not repeated herein.
The cosolvent may be present in an amount of 1%, 2%, 3%, 4%, 5%, 6%, or 7% by volume of the pet spray. Any other point value within the range can be selected, and the description is not repeated herein.
Preferably, the pet spray comprises the following components in mass concentration:
the balance of cosolvent and water;
wherein the cosolvent accounts for 3-5% of the volume ratio of the pet spray.
The raw material containing cannabidiol is calculated by compound cannabidiol in parts by mass. The raw material containing cannabidiol is preferably water-soluble cannabidiol.
Preferably, the pet spray further comprises a flavoring agent with the mass concentration of 0.03-0.3%, and the mass concentration of the flavoring agent can be 0.03%, 0.06%, 0.08%, 0.1%, 0.12%, 0.15%, 0.2%, 0.22%, 0.25%, 0.3% or the like. Any other point value within the range can be selected, and the description is not repeated herein.
The pet spray can be added with a flavoring agent according to actual needs.
Preferably, the flavoring agent is a water-soluble flavoring agent.
Preferably, the water-soluble flavoring agent comprises any one or a combination of at least two of sodium cyclamate, sucralose, or aspartame. The combination of at least two of the above-mentioned components, such as the combination of sodium cyclamate and sucralose, the combination of sucralose and aspartame, the combination of sodium cyclamate and aspartame, etc., can be selected in any other combination manner, and thus the details are not repeated herein.
Preferably, the menthol is levomenthol. Levo-menthol has a cooling effect and a mint flavor, and the racemate has a weak effect, but other isomers have no effect.
Preferably, the co-solvent is an alcoholic solvent.
Preferably, the alcoholic solvent includes any one of ethanol, propylene glycol or glycerin or a combination of at least two thereof. The combination of at least two of the above-mentioned materials, such as the combination of ethanol and propylene glycol, the combination of propylene glycol and glycerol, the combination of ethanol and glycerol, and the like, can be selected in any other combination manner, and thus, the description thereof is not repeated herein. The alcohol solvent is selected from safe edible alcohol solvents.
All components of the pet spray disclosed by the invention are food-grade.
In still another aspect, the present invention provides a method for preparing the pet spray as described above, the method comprising:
(1) mixing and stirring a raw material containing cannabidiol and water to obtain a solution 1; mixing menthol, thymol and cosolvent, and stirring to obtain solution 2;
(2) mixing and stirring the solution 1 and the solution 2 obtained in the step (1) to obtain a solution 3;
(3) mixing and stirring dimethyl sulfone, glucosamine sulfate, vitamin B2 and the solution 3 obtained in the step (2) to obtain a solution 4;
(4) mixing and stirring the active silver solution and the solution 4 obtained in the step (3) to obtain a solution 5;
(5) and (5) filtering the solution 5 obtained in the step (4) to obtain the pet spray.
The preparation method of the pet spray is simple and easy to implement.
Preferably, the flavoring agent is also added in the step (3) and mixed and stirred with the solution 3 obtained in the step (2).
In a further aspect, the invention provides an application of the composition for pets or the pet spray as described above in preparing a medicine for preventing and treating oral diseases, improving arthritis or relieving anxiety of pets.
Compared with the prior art, the invention has the following beneficial effects:
the components in the composition for the pet are matched with each other and have synergistic interaction, so that the composition for the pet can prevent and treat oral diseases of the pet, protect the oral health of the pet, effectively improve various symptoms caused by arthritis of the pet, and has the effects of relieving the irritability and anxiety of the pet and calming and relaxing the mood of the pet. The composition can be used for preparing pet spray, can be administered through oral mucosa, and has quick action and high bioavailability. The compositions or sprays of the present invention may also be used with other animals.
Detailed Description
To further illustrate the technical means and effects of the present invention, the following further describes the technical solution of the present invention with reference to the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.
The following examples and comparative examples relate to cannabidiol-containing materials (water-soluble cannabidiol) available from Yunnan Hansu Biotech, Inc. under the trade name: polyphenol Resin. The dosage is calculated by the compound cannabidiol.
Example 1
The embodiment provides a pet spray, which comprises the following components:
the preparation process comprises the following steps:
(1) mixing and stirring a raw material containing cannabidiol and purified water to obtain a solution 1; mixing levo-menthol, thymol and ethanol, stirring, and dissolving by ultrasonic to obtain solution 2;
(2) mixing and stirring the solution 1 and the solution 2 obtained in the step (1) to obtain a solution 3;
(3) mixing and stirring dimethyl sulfone, glucosamine sulfate, vitamin B2 and sucralose with the solution 3 obtained in the step (2) to obtain a solution 4;
(4) mixing and stirring the colloidal silver solution and the solution 4 obtained in the step (3) to obtain a solution 5;
(5) and (5) filtering the solution 5 obtained in the step (4) by using a 0.22-micrometer bacterial filtering membrane to obtain the pet spray.
Example 2
The embodiment provides a pet spray, which comprises the following components:
the preparation process comprises the following steps:
(1) mixing and stirring a raw material containing cannabidiol and purified water to obtain a solution 1; mixing levo-menthol, thymol and ethanol, stirring, and dissolving by ultrasonic to obtain solution 2;
(2) mixing and stirring the solution 1 and the solution 2 obtained in the step (1) to obtain a solution 3;
(3) mixing and stirring dimethyl sulfone, glucosamine sulfate, vitamin B2 and sucralose with the solution 3 obtained in the step (2) to obtain a solution 4;
(4) mixing and stirring the colloidal silver solution and the solution 4 obtained in the step (3) to obtain a solution 5;
(5) and (5) filtering the solution 5 obtained in the step (4) by using a 0.22-micrometer bacterial filtering membrane to obtain the pet spray.
Example 3
The embodiment provides a pet spray, which comprises the following components:
the preparation process comprises the following steps:
(1) mixing and stirring a raw material containing cannabidiol and purified water to obtain a solution 1; mixing levo-menthol, thymol and ethanol, stirring, and dissolving by ultrasonic to obtain solution 2;
(2) mixing and stirring the solution 1 and the solution 2 obtained in the step (1) to obtain a solution 3;
(3) mixing and stirring dimethyl sulfone, glucosamine sulfate, vitamin B2 and sucralose with the solution 3 obtained in the step (2) to obtain a solution 4;
(4) mixing and stirring the colloidal silver solution and the solution 4 obtained in the step (3) to obtain a solution 5;
(5) and (5) filtering the solution 5 obtained in the step (4) by using a 0.22-micrometer bacterial filtering membrane to obtain the pet spray.
Example 4
The embodiment provides a pet spray, which comprises the following components:
the preparation process comprises the following steps:
(1) mixing and stirring a raw material containing cannabidiol and purified water to obtain a solution 1; mixing and stirring levo-menthol, thymol and glycerol, and dissolving by ultrasonic to obtain a solution 2;
(2) mixing and stirring the solution 1 and the solution 2 obtained in the step (1) to obtain a solution 3;
(3) mixing and stirring dimethyl sulfone, glucosamine sulfate, vitamin B2 and sodium cyclamate with the solution 3 obtained in the step (2) to obtain a solution 4;
(4) mixing and stirring the colloidal silver solution and the solution 4 obtained in the step (3) to obtain a solution 5;
(5) and (5) filtering the solution 5 obtained in the step (4) by using a 0.22-micrometer bacterial filtering membrane to obtain the pet spray.
Example 5
The embodiment provides a pet spray, which comprises the following components:
the preparation process comprises the following steps:
(1) mixing and stirring a raw material containing cannabidiol and purified water to obtain a solution 1; mixing and stirring levo-menthol, thymol and propylene glycol, and dissolving the mixture by ultrasonic to obtain a solution 2;
(2) mixing and stirring the solution 1 and the solution 2 obtained in the step (1) to obtain a solution 3;
(3) mixing and stirring dimethyl sulfone, glucosamine sulfate, vitamin B2 and aspartame with the solution 3 obtained in the step (2) to obtain a solution 4;
(4) mixing and stirring the colloidal silver solution and the solution 4 obtained in the step (3) to obtain a solution 5;
(5) and (5) filtering the solution 5 obtained in the step (4) by using a 0.22-micrometer bacterial filtering membrane to obtain the pet spray.
Comparative example 1
The comparative example provides a pet spray, which comprises the following components:
the preparation process comprises the following steps:
(1) mixing levo-menthol, thymol and ethanol, stirring, and dissolving by ultrasonic to obtain solution 1;
(2) mixing and stirring the solution 1 obtained in the step (1) with purified water to obtain a solution 2;
(3) mixing and stirring dimethyl sulfone, glucosamine sulfate, vitamin B2 and sucralose with the solution 2 obtained in the step (2) to obtain a solution 3;
(4) mixing and stirring the colloidal silver solution and the solution 3 obtained in the step (3) to obtain a solution 4;
(5) and (5) filtering the solution 4 obtained in the step (4) by using a 0.22-micrometer bacterial filtering membrane to obtain the pet spray.
Comparative example 2
The comparative example provides a pet spray, which comprises the following components:
contains cannabidiol 10.245%
0.03 percent of sucralose
The balance of purified water;
the preparation process comprises the following steps:
mixing and stirring a raw material containing cannabidiol and purified water to obtain a solution 1; and mixing and stirring the sucralose and the solution 1, and filtering by using a 0.22-micron bacterial filter membrane to obtain the pet spray.
Comparative example 3
The comparative example provides a pet spray, which comprises the following components:
the specific preparation process is as in example 1.
Comparative example 4
The comparative example provides a pet spray, which comprises the following components:
the specific preparation process is as in example 1.
Comparative example 5
The comparative example provides a pet spray, which comprises the following components:
the specific preparation process is as in example 1.
Comparative example 6
The comparative example provides a pet spray, which comprises the following components:
the specific preparation process is as in example 1.
Comparative example 7
The comparative example provides a pet spray, which comprises the following components:
the specific preparation process is as in example 1.
Comparative example 8
The comparative example provides a pet spray, which comprises the following components:
the specific preparation process is as in example 1.
Test example 1
Evaluation of pet spray for treating periodontitis
(1) Preparing a bacterial liquid:
inoculating Porphyromonas gingivalis (P.gingivalis), Prevotella intermedia (P.intermedia) and Fusobacterium nucleatum (F.nucleatum) into nutrient broth culture medium, culturing at 37 deg.C under anaerobic condition for 2-5 days, selecting single colony on plate, preparing bacterial suspension 5mL with sterile PBS (50mmol/L, pH7.4), and adjusting to 0.5 McLeod turbidity concentration (i.e. 1 × 10)8CFU/mL), then adding carboxymethyl cellulose, filtering with a filter membrane with the aperture of 0.22 mu m, and preparing a fresh bacterial liquid containing 2% of carboxymethyl cellulose.
(2) Establishment of periodontitis animal model
Selecting 84 male Wistar rats with SPF level, weight of 200 +/-20 g, good activity, no caries and no periodontal disease. After the rat is anesthetized by injecting 3% sodium pentobarbital into the abdominal cavity at 1mg/kg, the second molar teeth on the upper jaw at the two sides are selected and tied to the neck of the tooth by using 5-0 medical silk threads, the ligature silk is put into the gingival sulcus as much as possible, and the ligature needs to be tied again when the ligature drops off. After ligation, the feed was fed with 10% glucose solution instead of drinking water, and 0.1mL of the prepared bacterial solution was inoculated every other day. After 28 days, 84 rats are visually observed with a Gingival Index (GI), a Plaque Index (PI) and a gingival probing bleeding index (BOP), the gingiva is obviously red and swollen, the second molar has soft dirt attached and is accompanied by automatic bleeding symptoms, the average gingival index of the rat is 3, the plaque index is 3, the probing bleeding index is 3, and the modeling is judged to be successful.
(3) Animal experiment grouping
The 84 rats successfully modeled were randomly divided into 14 groups of 6 rats each. The specific grouping is shown in Table 1, the medicine is taken twice a day, once in the morning and evening, 0.2mL is smeared in the oral cavity by using a disposable syringe, and the medicine is continuously taken for 28 days.
TABLE 1
| Group of | Type of administration |
| Blank control group | 0.9% physiological saline |
| Administration group 1 | Comparative example 1 |
| Administration group 2 | Comparative example 2 |
| Administration group 3 | Comparative example 3 |
| Administration group 4 | Comparative example 4 |
| Administration group 5 | Comparative example 5 |
| Administration group 6 | Comparative example 6 |
| Administration group 7 | Comparative example 7 |
| Administration group 8 | Comparative example 8 |
| Administration group 9 | Example 1 |
| Administration set 10 | Example 2 |
| Administration group 11 | Example 3 |
| Administration group 12 | Example 4 |
| Administration group 13 | Example 5 |
(4) Evaluation of Effect of treatment of periodontitis
The Gingival Index (GI), Plaque Index (PI), and bleeding index from probing (BOP) were measured and recorded using probes after 28 days of dosing. The experimental data are expressed by mean values +/-standard deviation, and the data are subjected to one-factor variance analysis, and the difference p less than 0.05 has significance. Oral index evaluation for each group 28 days after dosing is shown in table 2.
TABLE 2
As can be seen from the data in Table 2: after 28 days of administration, oral cavity indexes of the administration group are reduced compared with those of a blank control group, but the administration group 1-2 and the administration group 5-8 have no significant difference (p is more than or equal to 0.05) with the blank control group; compared with the blank control group, the oral cavity indexes of the administration groups 3-4 and the administration groups 9-13 are obviously reduced (p is less than 0.05), which shows that the compatibility of cannabidiol, menthol, thymol, vitamin B2 and active silver has synergistic effect on periodontitis.
Test example 2
Evaluation of effect of pet spray on treating osteoarthritis
(1) Laboratory animals and groups
60 healthy New Zealand white rabbits with four months age, common grade, half female and half male are selected and bred in cages with the weight of 2.5 +/-0.5 kg. The pet sprays prepared in examples 1 to 5 and comparative examples 1 to 8 were administered to the treatment groups, 4 of which were randomly divided into a normal group, a model group, and a treatment group, wherein the treatment groups were divided into 13 groups.
(2) Preparation of animal models
The animals are raised in cages and in a quiet environment at room temperature for one week. The test animals were molded by the Hulth method for each group except the normal group. The experimental animal is anesthetized by intraperitoneal injection with 3% sodium pentobarbital (40mg/kg) and fixed in a supine position, a longitudinal incision of about 2cm is made on the inner side of the right hind leg joint to expose the joint cavity, the anterior and posterior cruciate ligaments are cut off, the inner meniscus is completely cut off, the wound is closed layer by layer after the operative field is cleaned, and then dressing is used for bandaging. After operation, the intramuscular injection of penicillin is 20 ten thousand U/d for 3 days, thereby preventing infection.
(3) Method of administration
The normal group and the model group are fed with normal feed every day, the treatment group is started one week after the operation, the drug is taken twice every day, the drug is taken once in the morning and evening, 0.5mL of the drug is smeared in the oral cavity by adopting a disposable syringe every time, and the drug is continuously taken for 6 weeks.
(4) Obtaining experimental animal materials
After 6 weeks of administration, 1mL of double distilled water was injected into the joint cavity, followed by repeated aspiration with a syringe and then aspirated as much as possible, and stored at-20 ℃.
(5) Observation indicator and detection method
Taking out the joint fluid, centrifuging by a centrifugal machine, taking out supernatant, and detecting the content of NOS (nitric oxide synthase) and SOD (superoxide dismutase) in the joint fluid by a colorimetric method. The specific operation is as follows.
And (3) determination of NOS content: the reagents are prepared by adopting a nitric acid reductase method according to the specification of an NOS kit, 0.1mL of double distilled water is added into each test tube to serve as a blank tube, 0.1mL of supernatant is used as a measuring tube, and 0.1mL of standard solution is used as a standard tube. Adding 0.4mL of mixed reagent of the first reagent and the second reagent into each tube, mixing the mixture evenly, incubating the mixture in a water bath tank for 1h (37 ℃), continuously adding 0.4mL of the third reagent and the fourth reagent respectively, mixing the mixture evenly, standing the mixture for 30min, centrifuging the mixture, taking supernate, adding a color developing agent, standing the mixture for 10min at room temperature after color development, setting a spectrophotometer in the spectrophotometer, setting a wavelength of 550nm, setting a 0.5cm light diameter cuvette, adjusting the distilled water to zero, and determining the color.
And (3) measuring the SOD content: preparing a reagent by adopting a xanthine oxidase method according to the specification of an SOD determination kit, adding 1mL of the reagent into two test tubes, respectively adding 30 μ L of joint supernatant as a test tube, adding 30 μ L of a control tube, sequentially adding 0.1mL of the reagents into each tube respectively according to the specification process, uniformly mixing, incubating for 40min (37 ℃), adding 2mL of a color developing agent, standing for 10min after color development, setting the wavelength to be 550nm, adjusting the optical diameter of 1cm of a cuvette, adjusting the distilled water to zero, and determining.
(6) Evaluation of therapeutic Effect
The experimental data are expressed by mean values +/-standard deviation, and the data are subjected to one-factor variance analysis, and the difference p less than 0.05 has significance. The contents of NOS and SOD in the synovial fluid of each group are shown in Table 3.
TABLE 3
As can be seen from the data in Table 3: the NOS content in the joint fluid is obviously increased (P is less than 0.05) compared with the normal group; the treatment groups 1-5 and the treatment groups 10-13 are obviously reduced compared with the model group (P is less than 0.05); there was no significant difference between treatment groups 6-9 compared to model groups (P > 0.05). The SOD content in the joint fluid is obviously reduced compared with the normal group (P is less than 0.05); the treatment groups 1-5 and the treatment groups 10-13 are obviously increased compared with the model group (P < 0.05); the treatment groups 6-9 have no obvious difference (P is more than 0.05) compared with the model groups, which indicates that the compatibility of cannabidiol, glucosamine sulfate and dimethyl sulfoxide has synergistic effect on osteoarthritis.
The applicant states that the present invention is illustrated by the above examples to describe a pet composition and its application, but the present invention is not limited to the above examples, i.e. it is not meant that the present invention must rely on the above examples to be practiced. It should be understood by those skilled in the art that any modification of the present invention, equivalent substitutions of the raw materials of the product of the present invention, addition of auxiliary components, selection of specific modes, etc., are within the scope and disclosure of the present invention.
The preferred embodiments of the present invention have been described in detail, however, the present invention is not limited to the specific details of the above embodiments, and various simple modifications may be made to the technical solution of the present invention within the technical idea of the present invention, and these simple modifications are within the protective scope of the present invention.
It should be noted that the various technical features described in the above embodiments can be combined in any suitable manner without contradiction, and the invention is not described in any way for the possible combinations in order to avoid unnecessary repetition.
Claims (10)
1. A composition for pets, comprising a cannabidiol-containing material, dimethyl sulfone, glucosamine sulphate, menthol, thymol, vitamin B2 and active silver; the cannabidiol-containing material comprises a cannabidiol pure product, water-soluble cannabidiol, an industrial cannabis flower extract, an industrial cannabis leaf extract or a full spectrum cannabis oil.
2. The composition for pet animals as claimed in claim 1, wherein the composition for pet animals comprises, in parts by mass, 0.1-0.3 part of a cannabidiol-containing raw material, 3-8 parts of dimethyl sulfone, 3-8 parts of glucosamine sulfate, 0.02-0.15 part of menthol, 0.02-0.1 part of thymol, 0. 20.001-0.015 part of vitamin B and 0.1 x 10 parts of active silver-7-50×10-7Preparing; the raw material containing the cannabidiol is calculated by the cannabidiol in parts by mass.
3. A pet spray comprising the composition for pets of claim 1 or 2, a co-solvent, and water.
4. The pet spray of claim 3, wherein the pet spray comprises the following components in mass concentration:
wherein the cosolvent accounts for 1-7% of the volume ratio of the pet spray;
the raw material containing the cannabidiol is calculated by the cannabidiol in parts by mass.
5. The pet spray of claim 3 or 4, wherein the pet spray comprises the following components in mass concentration:
wherein the cosolvent accounts for 3-5% of the volume ratio of the pet spray;
the raw material containing the cannabidiol is calculated by the cannabidiol in parts by mass.
6. The pet spray of any one of claims 3-5, further comprising a flavoring agent at a mass concentration of 0.03-0.3%;
preferably, the flavoring agent is a water-soluble flavoring agent;
preferably, the water-soluble flavoring agent comprises any one or a combination of at least two of sodium cyclamate, sucralose, or aspartame.
7. The pet spray of any one of claims 3-6, wherein the menthol is levomenthol;
preferably, the cosolvent is an alcohol solvent;
preferably, the alcoholic solvent includes any one of ethanol, propylene glycol or glycerin or a combination of at least two thereof.
8. The method of making a pet spray of any one of claims 3-7, comprising:
(1) mixing and stirring a raw material containing cannabidiol and water to obtain a solution 1; mixing menthol, thymol and cosolvent, and stirring to obtain solution 2;
(2) mixing and stirring the solution 1 and the solution 2 obtained in the step (1) to obtain a solution 3;
(3) mixing and stirring dimethyl sulfone, glucosamine sulfate, vitamin B2 and the solution 3 obtained in the step (2) to obtain a solution 4;
(4) mixing and stirring the active silver solution and the solution 4 obtained in the step (3) to obtain a solution 5;
(5) and (5) filtering the solution 5 obtained in the step (4) to obtain the pet spray.
9. The method of claim 8, wherein the flavor is added in step (3) and mixed with the solution 3 obtained in step (2) and stirred.
10. Use of a composition for pets according to claim 1 or 2 or a pet spray according to any one of claims 3 to 7 for the manufacture of a medicament for preventing and treating oral diseases, improving arthritis or relieving anxiety in pets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911222101.2A CN111956664A (en) | 2019-12-03 | 2019-12-03 | Composition for pets and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911222101.2A CN111956664A (en) | 2019-12-03 | 2019-12-03 | Composition for pets and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111956664A true CN111956664A (en) | 2020-11-20 |
Family
ID=73358247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911222101.2A Pending CN111956664A (en) | 2019-12-03 | 2019-12-03 | Composition for pets and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111956664A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114533782A (en) * | 2021-12-20 | 2022-05-27 | 汉木森新药研发(深圳)有限公司 | Application of full-spectrum CBD oil in preparation of medicine for preventing or treating periodontitis |
| CN115990196A (en) * | 2021-10-18 | 2023-04-21 | 云南汉盟制药有限公司 | Antibacterial composition containing cannabidiol, and preparation method and application thereof |
| LU501323B1 (en) * | 2022-01-25 | 2023-07-25 | Kemijski Inst | Cannabinoid complexes with improved properties |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631406A (en) * | 2012-04-12 | 2012-08-15 | 徐柔云 | Mouthwash for oral ulcer |
| CN103143002A (en) * | 2013-03-29 | 2013-06-12 | 武汉中博绿亚生物科技有限公司 | Healthcare agent for pet bone joint and preparation method of healthcare agent |
| CN106620657A (en) * | 2015-11-02 | 2017-05-10 | 瑞普（天津）生物药业有限公司 | Healthcare agent for pet joints and preparation method thereof |
| WO2017178937A1 (en) * | 2016-04-13 | 2017-10-19 | Uab Satimed | The oleo gel composition and delivery system with active compounds from cannabis sativa and mentha arvensis for reduction of inflammation and pain in deep tissues |
| CN108685987A (en) * | 2018-06-25 | 2018-10-23 | 上海凯宝药业股份有限公司 | A kind of Chinese medicine composition and its preparation method and application |
| WO2019199861A2 (en) * | 2018-04-09 | 2019-10-17 | Ellevet Sciences | Hemp extract for treatment of pain in animals |
-
2019
- 2019-12-03 CN CN201911222101.2A patent/CN111956664A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102631406A (en) * | 2012-04-12 | 2012-08-15 | 徐柔云 | Mouthwash for oral ulcer |
| CN103143002A (en) * | 2013-03-29 | 2013-06-12 | 武汉中博绿亚生物科技有限公司 | Healthcare agent for pet bone joint and preparation method of healthcare agent |
| CN106620657A (en) * | 2015-11-02 | 2017-05-10 | 瑞普（天津）生物药业有限公司 | Healthcare agent for pet joints and preparation method thereof |
| WO2017178937A1 (en) * | 2016-04-13 | 2017-10-19 | Uab Satimed | The oleo gel composition and delivery system with active compounds from cannabis sativa and mentha arvensis for reduction of inflammation and pain in deep tissues |
| WO2019199861A2 (en) * | 2018-04-09 | 2019-10-17 | Ellevet Sciences | Hemp extract for treatment of pain in animals |
| CN108685987A (en) * | 2018-06-25 | 2018-10-23 | 上海凯宝药业股份有限公司 | A kind of Chinese medicine composition and its preparation method and application |
Non-Patent Citations (2)
| Title |
|---|
| 周艳丽等: "氨基葡萄糖和骨碎补联用对大鼠慢性骨关节炎的干预作用及机制", 《食品科学》 * |
| 柯晖: "怀牛膝对兔骨性关节炎软骨组织影响的实验研究", 《中国博士学位论文全文数据库 医药卫生科技辑2013年01期》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115990196A (en) * | 2021-10-18 | 2023-04-21 | 云南汉盟制药有限公司 | Antibacterial composition containing cannabidiol, and preparation method and application thereof |
| CN114533782A (en) * | 2021-12-20 | 2022-05-27 | 汉木森新药研发(深圳)有限公司 | Application of full-spectrum CBD oil in preparation of medicine for preventing or treating periodontitis |
| LU501323B1 (en) * | 2022-01-25 | 2023-07-25 | Kemijski Inst | Cannabinoid complexes with improved properties |
| WO2023144165A1 (en) * | 2022-01-25 | 2023-08-03 | Kemijski inštitut | Cannabinoid complexes with improved properties |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109646361B (en) | Composite biological deodorization spray for pets and preparation method thereof | |
| CN106176690B (en) | Hyaluronic acid oral care film and preparation method and application | |
| CN111956664A (en) | Composition for pets and application thereof | |
| EP2775838B1 (en) | Aqueous antimicrobial composition containing coniferous resin acids | |
| CN106794210A (en) | Comprising mangosteen extract or α, γ mangostin as the periodontosis prevention of active ingredient or improvement composition | |
| CN109316536A (en) | A kind of skin mucosa disinfecting agent and preparation method thereof | |
| CN110575432B (en) | Composition containing cannabidiol and application of composition in animal products | |
| EA018425B1 (en) | Pharmaceutical, disinfectant or preservation extract of trigonella foenum-graecum, method for preparing and use thereof | |
| CN105193665A (en) | Blumea balsamifera oral care solution, and preparation method and application thereof | |
| TW200911279A (en) | Compositions, uses, and method of making wound care products from naturally occurring food ingredients | |
| KR20120125317A (en) | Propolis and process for the treatment thereof and end products formed therefrom | |
| RU2527347C1 (en) | Stable liquid pharmaceutical composition of 3-(2,2,2-trimethylhydrazinium) propionate-2-ethyl-6-methyl-3-hydroxypyridine disuccinate complex, having antihypoxic, antioxidant and adaptogenic action | |
| CN110327246A (en) | A kind of mouthwash containing marine oligosaccharide | |
| CN109833431A (en) | A kind of bacteriostatic gel and preparation method thereof | |
| KR102358743B1 (en) | Oral disintegrating film composition for animals that has the effect of removing halitosis, removing tartar and, improving stomatitis and periodontitis | |
| Harris et al. | The Development and Evaluation of Melatonin-Loaded, Calcium Oxide Nanoparticle-Based Neem and Clove Extract: An In Vitro Study | |
| CN111658626B (en) | Pharmaceutical composition, preparation method and medical application thereof | |
| CN109453146B (en) | Pathogenic microorganism resisting composition and preparation method and application thereof | |
| KR100438209B1 (en) | Complex antimicrobial composition based on carvacrol, thymol, and citral | |
| US20170368123A1 (en) | Coniferous resin for treating and preventing sterile inflammation | |
| KR100822028B1 (en) | A pharmaceutical agent for preventing of alopecia and promoting hair restoration containing refined wood vinegar | |
| JP2003160502A (en) | Production method of active fraction obtained from pyroligneous acid and utilization thereof | |
| BR112021005603A2 (en) | formulation, and, methods for treating or preventing a pathogenic or wound infection, treating or preventing an oral infection, treating or preventing infection during or following a medical procedure, treating or preventing a fungal infection, administering the formulation, maintaining or improving health of an animal and disinfect a surface | |
| KR20030093891A (en) | PROPOLIS Toothpaste COMPOSITION AND PROCESS FOR PREPARING THE SAME | |
| RU2784726C1 (en) | Therapeutic and prophylactic toothpaste based on betulin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201120 |